This clinical trial investigates the maximum tolerated dosage of tucatinib combined with ado-trastuzumab emtansine in the treatment of patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases.
https://ift.tt/2IzAvjm
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου